Alkaline phosphatase in metastatic castration-resistant prostate cancer: Reassessment of an older biomarker

Daniel Heinrich, Oyvind Bruland, Theresa Guise, Hiroyoshi Suzuki, Oliver Sartor

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Since most patients with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, it is important to understand the potential impact of therapies on prognostic biomarkers, such as ALP. Clinical studies involving mCRPC life-prolonging agents (i.e., sipuleucel-T, abiraterone, enzalutamide, docetaxel, cabazitaxel, and radium-223) have shown that baseline ALP level is prognostic for overall survival, and may be a better prognostic marker for overall survival than prostate-specific antigen in patients with bone-dominant mCRPC. Mechanism of action differences between therapies may partly explain ALP dynamics during treatment. ALP changes can be interpreted within the context of other parameters while monitoring disease activity to better understand the underlying pathology. This review evaluates the current role of ALP in mCRPC.

Original languageEnglish (US)
Pages (from-to)2543-2556
Number of pages14
JournalFuture Oncology
Volume14
Issue number24
DOIs
StatePublished - Oct 1 2018

Fingerprint

Castration
Alkaline Phosphatase
Prostatic Neoplasms
Biomarkers
docetaxel
Radium
Bone Neoplasms
Survival
Prostate-Specific Antigen
Therapeutics
Pathology
Neoplasm Metastasis
Bone and Bones

Keywords

  • Alkaline phosphatase
  • Biomarker
  • Bone metastases
  • Castration-resistant prostate cancer
  • Mechanism of action
  • Prognostic marker
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Alkaline phosphatase in metastatic castration-resistant prostate cancer : Reassessment of an older biomarker. / Heinrich, Daniel; Bruland, Oyvind; Guise, Theresa; Suzuki, Hiroyoshi; Sartor, Oliver.

In: Future Oncology, Vol. 14, No. 24, 01.10.2018, p. 2543-2556.

Research output: Contribution to journalReview article

Heinrich, Daniel ; Bruland, Oyvind ; Guise, Theresa ; Suzuki, Hiroyoshi ; Sartor, Oliver. / Alkaline phosphatase in metastatic castration-resistant prostate cancer : Reassessment of an older biomarker. In: Future Oncology. 2018 ; Vol. 14, No. 24. pp. 2543-2556.
@article{e5b67ed47aef4278aaf9807741de03e0,
title = "Alkaline phosphatase in metastatic castration-resistant prostate cancer: Reassessment of an older biomarker",
abstract = "Since most patients with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, it is important to understand the potential impact of therapies on prognostic biomarkers, such as ALP. Clinical studies involving mCRPC life-prolonging agents (i.e., sipuleucel-T, abiraterone, enzalutamide, docetaxel, cabazitaxel, and radium-223) have shown that baseline ALP level is prognostic for overall survival, and may be a better prognostic marker for overall survival than prostate-specific antigen in patients with bone-dominant mCRPC. Mechanism of action differences between therapies may partly explain ALP dynamics during treatment. ALP changes can be interpreted within the context of other parameters while monitoring disease activity to better understand the underlying pathology. This review evaluates the current role of ALP in mCRPC.",
keywords = "Alkaline phosphatase, Biomarker, Bone metastases, Castration-resistant prostate cancer, Mechanism of action, Prognostic marker, Survival",
author = "Daniel Heinrich and Oyvind Bruland and Theresa Guise and Hiroyoshi Suzuki and Oliver Sartor",
year = "2018",
month = "10",
day = "1",
doi = "10.2217/fon-2018-0087",
language = "English (US)",
volume = "14",
pages = "2543--2556",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "24",

}

TY - JOUR

T1 - Alkaline phosphatase in metastatic castration-resistant prostate cancer

T2 - Reassessment of an older biomarker

AU - Heinrich, Daniel

AU - Bruland, Oyvind

AU - Guise, Theresa

AU - Suzuki, Hiroyoshi

AU - Sartor, Oliver

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Since most patients with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, it is important to understand the potential impact of therapies on prognostic biomarkers, such as ALP. Clinical studies involving mCRPC life-prolonging agents (i.e., sipuleucel-T, abiraterone, enzalutamide, docetaxel, cabazitaxel, and radium-223) have shown that baseline ALP level is prognostic for overall survival, and may be a better prognostic marker for overall survival than prostate-specific antigen in patients with bone-dominant mCRPC. Mechanism of action differences between therapies may partly explain ALP dynamics during treatment. ALP changes can be interpreted within the context of other parameters while monitoring disease activity to better understand the underlying pathology. This review evaluates the current role of ALP in mCRPC.

AB - Since most patients with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, it is important to understand the potential impact of therapies on prognostic biomarkers, such as ALP. Clinical studies involving mCRPC life-prolonging agents (i.e., sipuleucel-T, abiraterone, enzalutamide, docetaxel, cabazitaxel, and radium-223) have shown that baseline ALP level is prognostic for overall survival, and may be a better prognostic marker for overall survival than prostate-specific antigen in patients with bone-dominant mCRPC. Mechanism of action differences between therapies may partly explain ALP dynamics during treatment. ALP changes can be interpreted within the context of other parameters while monitoring disease activity to better understand the underlying pathology. This review evaluates the current role of ALP in mCRPC.

KW - Alkaline phosphatase

KW - Biomarker

KW - Bone metastases

KW - Castration-resistant prostate cancer

KW - Mechanism of action

KW - Prognostic marker

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85054423198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054423198&partnerID=8YFLogxK

U2 - 10.2217/fon-2018-0087

DO - 10.2217/fon-2018-0087

M3 - Review article

C2 - 29925281

AN - SCOPUS:85054423198

VL - 14

SP - 2543

EP - 2556

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 24

ER -